Detailed price information for Amicus Therapeutics (FOLD-Q) from The Globe and Mail including charting and trades.

Debut Biotech, a company innovating new molecules through advanced biotechnology, is partnering with Image Skincare to launch ...

However, Karp's exuberance about Palantir's Q3 results is warranted. The company blew past the consensus Wall Street revenue estimate of $1.09 billion. Its revenue growth accelerated from a 48% year ...

Still, the recently released 2025-30 Arizona Bioscience Roadmap, as well as several academic, community and local government ...

ASCO discussant Krina Patel, MD, of the University of Texas MD Anderson Cancer Center in Houston, noted, "Ciltacabtagene ...

Latin America faces a productivity crisis as industry declines and exports revert to raw materials, according to new ECLAC ...

Sana Biotechnology (SANA) shares have been trending higher over the past month, recording a 47% gain. This upward move comes as investors sort through recent developments and assess the company’s ...

– Phase 1 clinical trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in combination with androgen receptor pathway inhibitors in first-line mCRPC – Clinical ...

Investing.com -- Sana Biotechnology Inc (NASDAQ:SANA) stock surged 20% Wednesday after EMJ Capital Eric Jackson declared the company could become "the next 100-bagger platform" in a series of posts on ...

The launch of Rockcliffe Labs follows its acquisition of Algae-C Inc. , a biotechnology company with 14 patents and over 600 ...

COULD ACTUALLY BE MUCH MORE ACCURATE. A MARY SALADNA IS IN THE NEWSROOM AND MARY THE RESULTS AREN’T GOOD. NO, THEY’RE NOT, BUT THE RESULTS ARE MORE REALISTIC AND MORE PROOF THAT BODY COMPOSITION ...